Posts tagged as: clinical trials back to homepage
|
IntelGenx Reports Positive Results in Anti-Migraine Study(0) Quebec, Canada-based biotech IntelGenx Corp. (TSX-V:IGX) (OTCBB:IGXT) announced this morning the completion of the pivotal bioequivalence study for a novel oral thin-film formulation of Rizatriptan, the active drug in migraine medication Maxalt-MLT® orally disintegrating tablets. In December 2011, IntelGenx was approved by Health Canada to conduct a pivotal bioequivalence study to determine if IntelGenx’ product is safe and bioequivalent with the U.S. Food and Drug Administration approved reference product. Maxalt-MLT® is a leading branded anti-migraine product manufactured by Merck & Co. (NYSE: MRK). Read More |
|
InspireMD Completes Enrollment in Acute Myocardial Infarctions Study(0) Medical device maker InspireMD, Inc. (OTCBB: NSPR) said this morning that it has completed enrollment in its MASTER (MGuard™ for Acute ST Elevation Reperfusion) trial testing its stent platform technology for use in patients with Acute Myocardial Infarctions. The completion of enrollment has been achieved one month ahead of schedule, according Read More |
 |
Cellceutix Files Amended IND for Novel p53 Anti-Cancer Drug(0) The countdown has begun for Cellceutix to begin testing their lead compound, anti-cancer drug Kevetrin, at Dana-Farber and Beth Israel Deaconess. After a mild setback with Formatech going bankrupt, the company has completed the necessary changes to the Investigational New Drug application related to Quality Control testing and stability studies through a new supplier and added the data to the IND. This is great news for biotech traders and Cellceutix faithful as investors are eager to see the new drug in humans because Read More |
|
Fibrocell Submits Phase II Protocol for Burn Scars Treatment to FDA(0) Fibrocell Science, Inc. (OTCBB: FCSC), an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications, announced this morning that is has submitted to the U.S. Food & Drug Administration (FDA) the company’s Phase II clinical study protocol to evaluate the safety and efficacy of Fibrocell’s lead therapy, azficel-T, in improving the range of motion, function and flexibility, in patients with existing restrictive burn Read More |
|
Cellceutix Secures $1 Million; Clinical Trials on Tap for Cancer Drug(0) Mass High Tech ran the story last Thursday after Cellceutix Corporation (OTCBB: CTIX) submitted a regulatory filing with the Security and Exchange Commission related to securing the funds, but this morning the company released press discussing their securing of $1 million in financing for their planned clinical trials on Kevetrin™, their flagship anti-cancer drug. The trials are slated to be held at Harvard’s Dana-Farber Cancer Institute. Read More |
|
Cellceutix CEO Interview on TheStreetBeat Part II(0) Below is Part II of the CEO Interview from TheStreetBeat.com with Cellceutix CEO Leo Ehrlich, including the video and the text script. Read More |
|
Cellceutix CEO Leo Ehrlich Interviewed by TheStreetBeat.com(1) The latest edition of TheStreetBeat.com’s CEO Interview series features Cellceutix Chief Executive Officer Leo Ehrlich. The interview is being released in two parts, with Part One of the interview released this afternoon and Part Two slated Read More |
|
Cellceutix Novel Anti-Cancer Compound Kevetrin Presented at AACR Annual Meeting(0) Company on Schedule for Filing Amended IND - Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a biopharmaceutical company developing small molecule drugs to treat severe medical conditions, including drug-resistant cancers, is pleased to provide shareholders an update on developments with its novel anti-cancer compound Kevetrin™. Read More |
 |
Cellceutix Pens Agreement for Cancer Drug with Beth Israel Deaconess(0) Cellceutix Corporation (OTCBB:CTIX) continues to align itself with the biggest names in oncology research in the world. This truly sets the company apart from most of it developmental peers, regardless of exchange-listing or size. The company has released news recently about FDA document submissions seeking guidance on 505(b)(2) clearance for its psoriasis drug (which has provider stellar pre-clinical data) in addition to the clinical trials for its flagship cancer drug, Kevetrin™, which should be starting at Dana-Farber in the coming months. Read More |
 |
Cellceutix Files Pre-IND Documentation with FDA for New Psoriasis Drug(0) Company Gets Started on Next Drug in Their Pipeline Cellceutix Corporation (OTCBB: CTIX) (“the Company”), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, is pleased to report that it has filed a pre-IND submission with the U.S. Food and Drug Administration (FDA) on Prurisol™ (also termed “KM-133″), the Company’s drug in development as a novel treatment for psoriasis. Read More |
OTCBB News
read more
Stay Informed
Dana-Farber to Host Cellceutix Trials
Diabetes Rate Growing Exponentially
According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.
